MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2024 International Congress

    The impact of long-term continuous subcutaneous apomorphine infusion on the reduction of remaining medications in levodopa equivalent dosage and on increasing plasma vitamin B12 levels in patients with advanced Parkinson’s disease

    O. Phokaewvarangkul, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To evaluate the plasma levels of vitamin B and homocysteine among 28 advanced PD patients with motor complications before and after continued used of…
  • 2024 International Congress

    When Off Can Cost Life: Myocardial Infarction Due to Spontaneous Coronary Dissection as a Catastrophic Manifestation in Advanced Parkinson’s Disease.

    S. Poveda, T. Lopez, B. Pascual Sedano, A. Campolongo (Bogotá, Colombia)

    Objective: Describe a patient with PD who suffered an acute myocardial infarction during a severe OFF period. Background: Advanced PD is characterized by complications including…
  • 2024 International Congress

    Personality may influence the response to apomorphine infusion in Parkinson’s disease patients

    M. Boussac, E. Harroch, C. Barthelemy, F. Ory-Magne, C. Leung, M. Fabbri, C. Arbus, C. Brefel-Courbon (Toulouse, France)

    Objective: to evaluate the impact of personality on quality-of-life (QoL) amelioration after treatment by Continuous Subcutaneous Apomorphine Infusion (CSAI) in Parkinson’s disease (PD). Background: PD…
  • 2024 International Congress

    Continuous Subcutaneous Apomorphine Infusion (CSAI) Improved Confidence When Engaging in Everyday Activities: Survey of InfusON Study Participants

    P. Agarwal, A. Formella, N. Crouse, A. Breiteneicher, M. Grall (Kirkland, USA)

    Objective: Evaluate participants' perceptions of their confidence when engaging in daily activities and interpersonal relationships while using CSAI therapy, relative to the period before CSAI…
  • 2024 International Congress

    Patient Experiences Initiating Continuous Subcutaneous Apomorphine Infusion (CSAI): An Interview-Based Survey of InfusON Study Participants

    P. Agarwal, N. Crouse, A. Breiteneicher, M. Formella (Kirkland, USA)

    Objective: Obtain patient feedback on experiences initiating and using continuous subcutaneous apomorphine infusion (CSAI). Background: Previously reported data from the ongoing InfusON study demonstrated that…
  • 2023 International Congress

    Clinic versus home dose optimization of apomorphine sublingual film in Parkinson’s Disease: cross-study comparison of safety

    SH. Isaacson, J. Kassubek, R. Pahwa, E. Pappert, S. Wu, C. Denecke Muhr (Boca Raton, USA)

    Objective: To compare the safety profile of clinic versus home dose optimization of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease experiencing OFF episodes.…
  • 2023 International Congress

    Apomorphine sublingual film for OFF episodes in PD: Impact on orthostatic hypotension during dose-optimization

    W. Jost, M. Coelho, M. Fonseca, G. Castilla-Fernández, D. Magalhães, CK. Denecke Muhr (Wolfach, Germany)

    Objective: To assess the occurrence of orthostatic hypotension (OH) during apomorphine sublingual film (SL-APO) dose-optimization in patients with Parkinson’s disease (PwPD). Background: SL-APO has been…
  • 2023 International Congress

    Apomorphine effects on Parkinson’s disease fluctuation related pain: a pilot study

    P. Alizadeh, V. Bruno, K. Naser, A. Abusarair, B. Achen (Calgary, Canada)

    Objective: To evaluate the effect and safety of subcutaneous apomorphine as a treatment for fluctuation-related pain in Parkinson's disease (PD). Background: Pain is one of…
  • 2023 International Congress

    VALIdation of models for assessing eligibility for referral for Device-Aided Treatment in Parkinson’s disease (VALIDATE)

    H. Moes, E. Buskens, A. Portman, B. van Harten, M. van Kesteren, T. Mondria, L. Teune, E. van Wensen, M. van Onna, M. Schilperoord, A. Wertenbroek, M. Tjepkema-Cloostermans, L. Dorresteijn, T. van Laar (Groningen, Netherlands)

    Objective: To externally validate the Dutch Device-Aided Therapy Screening tool (D-DATS) and to compare it with the 5-2-1 criteria. Background: Timely identification of patients with…
  • 2023 International Congress

    Early onset of efficacy during titration in US phase 3 open-label InfusON trial of apomorphine subcutaneous infusion for Parkinson’s disease motor fluctuations

    S. Isaacson, G. Ceresoli-Borroni, A. Espay, R. Pahwa, P. Agarwal, H. Shill, J. Hui, K. Dashtipour, M. Lew, P. Qin, P. Lewitt (Boca Raton, USA)

    Objective: Evaluate safety/onset of efficacy during titration of continuous subcutaneous apomorphine infusion (CSAI) for motor fluctuations in U.S. outpatients with Parkinson’s disease (PD). Background: Global…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 14
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley